Cantor Fitzgerald downgraded Jasper Therapeutics (JSPR) to Neutral from Overweight.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile
- Jasper Therapeutics price target lowered to $20 from $64 at BTIG
- Jasper Therapeutics downgraded to Market Perform at William Blair
- Buy Rating Affirmed for Jasper Therapeutics Amid Promising Efficacy and Resolved Trial Setbacks
- Jasper Therapeutics price target lowered to $20 from $40 at H.C. Wainwright